Correlation Engine 2.0
Clear Search sequence regions


  • 1 receptor (34)
  • acid (2)
  • adopt (1)
  • adults (2)
  • albuminuria (1)
  • alemtuzumab (2)
  • allograft (2)
  • angina (1)
  • antidiabetics (6)
  • appears (2)
  • asthma (1)
  • basiliximab (2)
  • belatacept (5)
  • blood (5)
  • blood brain barrier (1)
  • calcineurin (8)
  • canagliflozin (3)
  • cardiovascular disease (15)
  • cardiovascular system (2)
  • case (9)
  • case reports (2)
  • central obesity (1)
  • cholesterol (1)
  • concept (4)
  • control group (1)
  • corticosteroid (11)
  • dapagliflozin (2)
  • death causes (5)
  • diagnosis (4)
  • dialysis (3)
  • disease and (2)
  • diseases liver (1)
  • diuresis (1)
  • dropouts (2)
  • dysglycemia (1)
  • eGFR (9)
  • endothelin 1 (1)
  • erythropoiesis (1)
  • exert (4)
  • factors (2)
  • foam cells (1)
  • focus (1)
  • GLP 1 (3)
  • GLP1 (10)
  • GLP1R (1)
  • gluc (2)
  • glucagon (6)
  • glucagon- like (32)
  • glucagon‐ receptor (2)
  • glucosuria (2)
  • gold (1)
  • graft (10)
  • heart (12)
  • heart failure (13)
  • heart rate (1)
  • heart transplant (3)
  • help (1)
  • hematocrit (1)
  • hemodialysis (1)
  • hemoglobin (1)
  • HIF 1 (1)
  • human body (1)
  • humans (1)
  • hydrogen (1)
  • hyperglycaemia (17)
  • hypovolemia (1)
  • hypoxia (1)
  • il2 receptor (1)
  • immunosuppressants (1)
  • impaired (10)
  • incretin effect (1)
  • incretin effect (1)
  • insight (1)
  • insulin (29)
  • ketoacidosis (1)
  • ketones (1)
  • ketosis (1)
  • ldl (3)
  • levels drug (1)
  • lipids (1)
  • lipoprotein (2)
  • liver (5)
  • liver transplant (5)
  • long term effect (2)
  • lung (1)
  • lung transplant (2)
  • mass (2)
  • meta analysis (3)
  • metformin (8)
  • morbid obesity (1)
  • natriuresis (3)
  • nervous system (1)
  • nitrogen (1)
  • other organs (1)
  • oxygen (2)
  • patients (80)
  • periods (6)
  • phase (2)
  • pilot study (1)
  • placebo (21)
  • plasma (5)
  • proteinuria (1)
  • protocol (3)
  • psoriasis (1)
  • reason (1)
  • registry (2)
  • renal blood flow (1)
  • renal disease (2)
  • renal function (1)
  • renal plasma flow (1)
  • renin– angiotensin– system (1)
  • research (3)
  • risk disease (2)
  • risk factors (6)
  • serum (5)
  • SGLT2 (4)
  • sign (2)
  • signal (1)
  • sirolimus (5)
  • sirolimus (5)
  • sodium (4)
  • sodium- glucose- linked transporter 2 inhibitor... (35)
  • spain (1)
  • steroid (1)
  • stroke (10)
  • suggest (4)
  • supply (1)
  • t cell (6)
  • tacrolimus (21)
  • therapies (2)
  • tubuloglomerular feedback (4)
  • uric acid (2)
  • urosepsis (1)
  • vas (1)
  • waist circumference (1)
  • weak (3)
  • weight (7)
  • weight gain (1)
  • weight loss (4)
  • Sizes of these terms reflect their relevance to your search.

    Post-transplant diabetes mellitus (PTDM) shows a relationship with risk factors including obesity and tacrolimus-based immunosuppression, which decreases pancreatic insulin secretion. Several of the sodium-glucose-linked transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) dramatically improve outcomes of individuals with type 2 diabetes with and without chronic kidney disease, which is, as heart failure and atherosclerotic cardiovascular disease, differentially affected by both drug classes (presumably). Here, we discuss SGLT2is and GLP1-RAs in context with other PTDM management strategies, including modification of immunosuppression, active lifestyle intervention, and early postoperative insulin administration. We also review recent studies with SGLT2is in PTDM, reporting their safety and antihyperglycemic efficacy, which is moderate to low, depending on kidney function. Finally, we reference retrospective case reports with GLP1-RAs that have not brought forth major concerns, likely indicating that GLP1-RAs are ideal for PTDM patients suffering from obesity. Although our article encompasses PTDM after solid organ transplantation in general, data from kidney transplant recipients constitute the largest proportion. The PTDM research community still requires data that treating and preventing PTDM will improve clinical conditions beyond hyperglycemia. We therefore suggest that it is time to collaborate, in testing novel antidiabetics among patients of all transplant disciplines. © 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.

    Citation

    Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Jenssen. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transplant international : official journal of the European Society for Organ Transplantation. 2020 Nov 28;34(1):27-48


    PMID: 33135259

    View Full Text